4D Molecular Therapeutics (FDMT) Cash from Investing Activities (2020 - 2026)

4D Molecular Therapeutics (FDMT) has 7 years of Cash from Investing Activities data on file, last reported at $68.9 million in Q1 2026.

• On a quarterly basis, Cash from Investing Activities rose 115.63% year-over-year to $68.9 million in Q1 2026; TTM through Mar 2026 was -$56.0 million, a 674.9% decrease from a year earlier, with the FY2025 full-year figure at -$93.0 million, up 69.26% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at $68.9 million, up from -$128.8 million in the prior quarter.
• Over the last five years, Cash from Investing Activities for FDMT reached as high as $68.9 million in Q1 2026 and fell as low as -$263.3 million in Q1 2024.
• Historically, Cash from Investing Activities has averaged -$13.4 million across 5 years, with a median of $15.4 million in 2022.
• On a YoY basis, Cash from Investing Activities climbed as much as 7897.56% in 2022 and fell as far as 8328.35% in 2022.
• Year by year, Cash from Investing Activities stood at -$35.8 million in 2022, then surged by 81.32% to -$6.7 million in 2023, then soared by 205.64% to $7.1 million in 2024, then tumbled by 1925.29% to -$128.8 million in 2025, then soared by 153.46% to $68.9 million in 2026.
• Per Business Quant data, the three most recent Cash from Investing Activities figures were $68.9 million in Q1 2026, -$128.8 million in Q4 2025, and $17.8 million in Q3 2025.